BioCryst Pharmaceuticals GAAP EPS of $1.12 beats by $1.07, revenue of $406.55M beats by $255.23M

BioCryst Pharmaceuticals reported a GAAP EPS of $1.12, significantly beating estimates, and revenue of $406.55 million, also exceeding expectations.